Cyteir synthetic lethality compound prompts Novo to lead $40M investment

Cyteir is Novo Holdings’ first investment in the DNA damage repair space

After bringing its lead candidate to the clinic, Cyteir raised $40.2 million in a series B extension to propel the first-in-class RAD51 inhibitor to clinical proof of concept and enable the development of a second synthetic lethality candidate.

Tuesday’s raise brings the round’s total to $75.2 million, more than a year after the first

Read the full 544 word article

User Sign In